NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma

• A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open label, study of CC-95266 in subjects with relapsed and/or refractory multiple myeloma. The study will consist of two parts: dose escalation (Part A) and dose expansion (Part B). The dose escalation (Part A) of the study will evaluate the safety and tolerability of increasing doses of CC-95266 in a single administration to establish a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D), and the dose expansion (Part B) of the study will further evaluate the safety, pharmacokinetics (PK)/ pharmacodynamics (PD), and efficacy of CC-95266 at the RP2D.

Sponsor

Juno Therapeutics, a Subsidiary of Celgene

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT04674813

Official Title: A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma

First Posted : December 19, 2020

Click here for details on ClinicalTrials.gov

Click here for details on cancer.gov

---

CC-95266

Multi-center phase I of GPRC5D-Targeted CARs

---

Drug: CC-95266

Drug: Fludarabine

Drug: Cyclophosphamide

---

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- Tennessee: Sarah Cannon Research Institute Nashville

- Texas: UT Southwestern Medical Center Dallas

---

Locations

United States, Alabama

United States, California

United States, Colorado

United States, Maryland

United States, Massachusetts

United States, New York

United States, Tennessee

United States, Texas

United States, Washington